Galmed Pharmaceuticals Ltd. filed its quarterly report for the three months ending March 31, 2025, with a net loss of $1.1 million and total assets of $18.7 million. The company aims to advance its product development strategies while facing a significant accumulated deficit of $201.6 million as of the reporting period.